-
Nanjing, China — June 1, 2025 — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-ba
-
Nanjing, China — April 24, 2025 — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”) today announced that two of its innovative oncology assets, LBL-024 and LBL-007, have been selected for oral and poster presentations, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual Mee
-
The 2025 American Association for Cancer Research® (AACR) annual meeting will be held in Chicago, USA, from April 25 to 30. Nanjing Leads Biolabs (Leads Biolabs) will unveil the latest research results of four preclinical pipelines during a poster session, including LBL-054-CD3 (an anti-CDH17 and CD
-
In February 2025, the Phase Ib/II clinical trial results of LBL-007, a novel LAG-3 antibody independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs"), was published in the prestigious Journal of Hematology & Oncology (Impact Factor: 29.9). This study, le
-
The 66th Annual Meeting of the American Society of Hematology (ASH 2024) will take place in San Diego, California, from December 7th to 10th. LBL-034, a humanized bispecific T-cell engager targeting both GPRC5D and CD3 which is independently developed by Nanjing Leads Biolabs Co., Ltd. (hereinafter
-
NANJING, China, November 22, 2024 -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendocrine cancer
-
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody
-
NANJING, China, November 1st, 2024--Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with global intellectual property r
-
NANJING, China, October 9, 2024--Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently develop
-
NANJING, China, September 27, 2024— Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the most recent clinical research findings of LBL-024, an anti-PD-L1/4-1BB bispecific antibody, and LBL-007, an anti-LAG-3 antibody, were showcased in an